EDAN(SZ:300206)2023-04-28 06:06Financial Performance - In Q1 2023, the company achieved revenue of 640 million CNY, a year-on-year increase of 64% [3] - Net profit attributable to shareholders was 140 million CNY, up 183% year-on-year [3] - Net profit after deducting non-recurring gains and losses reached 137 million CNY, reflecting a 312% year-on-year growth [3] Product Line Growth - All five major hardware product lines experienced year-on-year growth, with significant increases in patient monitoring and in vitro diagnostics [3] - The company anticipates continued growth across all product lines in the upcoming quarters, leveraging last year's performance as a benchmark [3][4] Market Expansion - Both domestic and international businesses saw year-on-year growth, with international business achieving double-digit growth [3] - The company has established eight overseas subsidiaries since 2006, focusing on localizing and legalizing operations in international markets [3][4] Future Outlook - The company aims for a revenue growth rate of 20-30% in the coming years, supported by its existing business layout and market capabilities [5] - The net profit margin is expected to improve from around 14% to approximately 20% over the next few years, driven primarily by sales growth [5] New Product Launches - The company continues to invest in R&D, with new products like the ix series patient monitors and i20 blood gas analyzers expected to contribute to sales starting this year [4] Artificial Intelligence Integration - AI has been integrated into medical devices, enhancing diagnostic efficiency and improving service delivery [4] - The company's ultrasound products utilize AI for high-performance, flexible, and cost-effective imaging analysis [4]